In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites. (Q38997358)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Gordana Wozniak Knopp

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Max Woisetschläger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Bernhard Antes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Radha Borrowdale

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Susanne Wiederkum

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Manuela Kainer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Kevin Moulder

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Florian Rüker

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Geert C Mudde

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

8 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

published in

Biotechnology Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

844-851

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

A new therapeutic antibody masks ErbB2 to its partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Resistance to human epidermal growth factor receptor type 2-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201300387

21 January 2018

Identifiers

DOI

10.1002/BIOT.201300387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24806546%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference